Penile Cancer clinical trials at UCSD
1 research study open to eligible people
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
open to eligible people ages 18 years and up
This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare genitourinary carcinomas and any genitourinary carcinoma with neuroendocrine differentiation. Given preliminary results, the study is being tested in additional patients with bladder or upper tract carcinoma with variant histology at this time while the adrenocortical carcinoma, other rare genitourinary malignancies arms have closed to accrual -The names of the study drugs involved in this study are: - Nivolumab - Ipilimumab
La Jolla, California and other locations
Our lead scientists for Penile Cancer research studies include Rana McKay, MD.